GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Gene Therapy, Springer Science and Business Media LLC, Vol. 27, No. 1-2 ( 2020-02), p. 89-97
    Type of Medium: Online Resource
    ISSN: 0929-1903 , 1476-5500
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 1212513-1
    detail.hit.zdb_id: 2004200-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Heliyon, Elsevier BV, Vol. 10, No. 5 ( 2024-03), p. e27107-
    Type of Medium: Online Resource
    ISSN: 2405-8440
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2024
    detail.hit.zdb_id: 2835763-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 12 ( 2022-12-15)
    Abstract: In this manuscript, we report torque teno mini virus (TTMV) as a cause of acute promyelocytic leukemia (APL) lacking PML :: RARA in a 3-year-old boy. Astolfi et al. firstly identified partial integration of the TTMV genome into RARA intron 2, which resulted in in-frame TTMV :: RARA fusion in two APL-like pediatric cases without PML :: RARA in November 2021. This fascinating report identified an unexpected exogenous genetic cause of APL and could be of great importance for diagnosing and managing APL. Here we report the third childhood APL-like case caused by TTMV integration and investigate the location and structure of the integrated TTMV sequence. These findings suggest TTMV :: RARA is a recurrent cause of APL lacking PML :: RARA . Considering the widespread prevalence of TTMV in the population, more TTMV :: RARA positive APL-like cases might remain to be identified. Establishing a bioinformatic analysis strategy optimized for the highly variable TTMV genome sequence may facilitate the identification of TTMV :: RARA by whole transcript sequencing. An effective PCR protocol to identify TTMV :: RARA based on a profound analysis of the conservation of TTMV segments in the fusion transcript is also expected. Also, further investigation is needed to elucidate the oncogenic mechanisms of TTMV integration and the clinical features of TTMV :: RARA positive patients.
    Type of Medium: Online Resource
    ISSN: 2234-943X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2022
    detail.hit.zdb_id: 2649216-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Molecular Carcinogenesis, Wiley, Vol. 62, No. 5 ( 2023-05), p. 665-675
    Abstract: This study aimed to investigate the relationship between anomalous DNA nucleotidylexotransferase ( DNTT ) activation and the mutagenesis of gene length mutations (LMs) in acute myeloid leukemia (AML), and the relevance of their prognosis in antithymocyte globulin (ATG)‐based regimen allogeneic hematopoietic stem cell transplantation (allo‐HSCT). A cohort of 578 AML cases was enrolled. Next‐generation sequencing was performed to screen mutations of 86 leukemia driver genes. RNA‐seq was used to analyze gene expression. Prognostic analysis was investigated in 239 AML cases who underwent ATG‐based regimen allo‐HSCT. We report a refined subtyping algorithm of LMs (type I–IV) based on sequence anatomy considering the TdT‐aided mutagenesis mechanism. GC content adjacent to LM junctions, inserted nontemplate nucleotide bases, and DNTT expression analysis supported the DNTT activation and TdT‐aided mutagenesis in type II/III LMs in the total AML cohort. Both single‐variate and multivariate analyses showed a better overall survival of FLT3 type III compared to type I in a subset of ATG‐based regimen allo‐HSCT cases. The novel LM subtyping algorithm not only deciphers the etiology of the mutagenesis of LMs but also helps to fine‐tune prognosis differentiation in AML. The possible prognostic versatility of this novel LM subtyping algorithm in terms of chemotherapy, targeted therapy, and allo‐HSCT merits further investigation.
    Type of Medium: Online Resource
    ISSN: 0899-1987 , 1098-2744
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2001984-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 2387-2387
    Abstract: Introduction B-cell acute lymphoid leukemia (B-ALL) with t(17;19)(q22;p13)/TCF3-HLF is very rare and has a dismal prognosis even with the application of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Due to the rarity of this fusion, only a few cases have been described in the literature. In this study, we retrospectively analyzed 24 cases with TCF3-HLF from a large cohort of B-ALL, which constituted the largest cohort of TCF3-HLF-positive ALL reported to date and reported in detail the laboratory characteristics and prognoses of this group of patients. Methods From Apr. 2012 to Feb. 2020, a total of 3287 cases were diagnosed with B-ALL in our hospital. All of them underwent afusion gene screening test including TCF3-HLF through multiplex-nested reverse transcription-PCR. Whole transcriptome sequencing (WTS) was performed using RNA extracted from the bone marrow (BM) samples by HiSeq 2500. The gene expression signature for TCF3-HLF-positive B-ALL was investigated by comparing with healthy controls, B-ALL with TCF3-PBX1/TCF3-ZNF384, and B-ALL negative for pathogenic fusion genes (Chen X et al., Blood Cancer J 2021). Results A total of 24 cases with TCF3-HLF were identified, accounting for 0.73% of all B-ALL cases. Among them, 22 (91.67%) were children (≤18 years), and 2 (8.33%) were adults. Length of follow-up varied. The endpoint of the follow-up was Jul. 1st, 2020. Overall survival (OS) was defined as the time from diagnosis to death or the time of the last follow-up. Of the 24 cases with TCF3-HLF, 8 had type I, 12 had type II, 4 had both type II and III chimera isoforms. Karyotype was available in 22 cases, 19 showed abnormal karyotypes and most of them (12/19, 63%) harbored further structural and/or numerical aberrations besides t(17;19)(q22;p13) translocation. Gene mutation screening of 58 genes was performed on 17 cases at the time of diagnosis. Eight (47%) of them showed mutations and 7 of them had mutations involving RAS signaling pathway genes (NRAS, KRAS, FLT3, and PTPN11). Immunophenotypic examination showed 12 (50%) and 19 (79%) patients exhibited aberrant expression of CD13 and CD33, only 4 patients (17%) were negative of both CD13 and CD33. Gene expression clustering revealed apparent separation of TCF3-HLF-positive cases from TCF3-PBX1/TCF3-ZNF384-positive cases and those without pathogenic fusions. The differential expression of 535 genes (up: 207, down: 328) was identified in TCF3-HLF-positive cases compared to TCF3-PBX1-positive cases. The differential expression of 471 genes (up: 281, down: 190) was identified in TCF3-HLF-positive cases compared to TCF3-ZNF384-positive cases. TCF3-HLF-positive patients displayed a significantly up-regulated expression of HLF, which was almost not expressed in other cases (Figure 1). The median OS of the 24 patients was 18.5 months (range 6-75 months). Thirteen of them underwent allogeneic HSCT (allo-HSCT) and the median OS was 23 months (range 13-75 months). Eight of them were in complete remission (CR) until the last follow-up; 2 of them relapsed after a first allo-HSCT and survived in CR after a second allo-HSCT; 3 of them died (2 died of relapse and 1 died of lung infection under CR). Eleven cases did not receive allo-HSCT, and the median OS was 9 months (range 6-29 months). Seven of them died (6 died after relapse, 1 died without achieving remission); 3 of them relapsed and re-induction was failed; only one case has survived in CR for 19 months till the last follow-up. Twelve cases underwent chimeric antigen receptor T-cells (CAR-T) therapy. Nine of them achieved CR after CAR-T therapy and bridged to allo-HSCT; one case achieved CR after CAR-T therapy but relapsed and lost opportunity for allo-HSCT; the other 2 patients achieved CR after the first application of CAR-T therapy but failed to achieve CR again by CAR-T therapy when relapsed. Conclusions We provide systematic insights into the laboratory characteristics and prognoses of B-ALL cases with TCF3-HLF in a large cohort. TCF3-HLF-positive B-ALL has a characteristic gene expression profile that differs markedly from TCF3-PBX1 and TCF3-ZNF384-positive B-ALL and shows a dismal prognosis. TC3F-HLF-positive ALL remains an incurable disease, although CAR-T therapy and allo-HSCT can improve the prognosis to some extent. Advanced therapeutic approaches, including novel drug discovery and development, are urgently required to improve the outcome of this ALL subtype. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2021
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 2243-2243
    Abstract: The clinical manifestations, management, and prognosis of acute promyelocytic leukemia (APL) are distinctive in acute myeloid leukemia (AML). Administration of all-trans retinoic acid (ATRA) and arsenic agents have greatly improved the outcome of APL from the most lethal to the most curable subtype AML. Unfortunately, relapse is still observed. And in the case of combined medication with ATRA and arsenic, the resistance mutation spectrum of PML-RARA is far from being revealed. We retrospectively analyzed 40 APL patients that admitted to our hospital from Jan. 2013 to Jul. 2020. There were 21 males and 19 females, aged 6-65 years (median age 31.5), and follow-up time was 3-210 months (median time 58.85 months). There were 3 cases that developed secondary tumors, although APL remission has been achieved. One developed refractory AML with KMT2A-MLLT3 fusion during the consolidation treatment one year after the diagnosis of APL. One case relapsed with APL 5 years after the initial diagnosis, and she developed refractory AML with RUNX1-MECOM fusion 3.5 years more after enduring multiple relapses and treatment courses. Another case developed AML-M2 3.5 years after the initial diagnosis of APL, and achieved sustained remission again through allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 8 cases came to our hospital at the initial onset of APL, and 1 came during remission. All these cases got sustained remission through combined triple therapy (ATRA, arsenic, and chemotherapy), with the follow-up time of 3 to 37 months (median 20.5 months). No PML-RARA resistant mutation was detected in these 9 cases. A total of 28 cases came to our hospital after APL relapse. The time from APL onset to the first relapse was 9-189 months (median 34 months). PML-RARA resistance mutations were detected in 9 cases, including 8 cases that carry single RARA mutations each, and 1 case that relapsed with multiple extramedullary infiltrations carry quadruple mutations (PML S214L-A216T and RARA R276W-H298N) (Figure 1a and b). A total of 4 cases underwent allo-HSCT after APL relapse. One of them relapsed 6 months after allo-HSCT, and the other 3 got sustained remission with the follow-up time of 47, 39, and 52 months, respectively. There were 2 cases relapsed after maintaining sustained remission for more than 5 years. One was a 58-year-old male who achieved sustained remission after 2.5 years of combined triple therapy. However, APL recurred 16 years after the primary diagnosis. He achieved remission again and now underwent the consolidation course of combined triple therapy. Another was a 23-year-old male who achieved sustained remission after combined arsenic and chemotherapy, but APL relapsed 75 months after the primary diagnosis. He was resistant to combined triple therapy and achieved remission through allo-HSCT. We failed to retrieve archived specimens at the first onset of APL for genomic variation comparison with the second onset. Therefore, we could not determine whether these two cases were relapsed from the original APL or developed another APL. Although we have achieved a high remission rate and long-term survival for APL through combined triple therapy, relapse and secondary tumors still occur in some cases. Especially for cases that endure heavy treatment, genomic toxicity may promote the oncogenesis of secondary tumors. Also, APL may recur over 5 years after the primary diagnosis and sustained remission. Whether there were inherited predisposing factors in these cases is worthy of further investigation. The incidence of PML and RARA resistant mutations in cases resistance for ATRA and arsenic is not very high. This may be related to the combination use of chemotherapeutic drugs and suggests underlying resistance mechanisms. Although both ATRA and arsenic were used in most cases, the incidence of ATRA resistance mutations is significantly higher than that of arsenic, which might attribute to the sparse interaction sites of arsenic and PML. A better combination strategy of arsenic, ATRA, with or without chemotherapy is worthy of further investigation to reduce the incidence of secondary tumors and relapse. Adhering to a systematically planed treatment course is essential for acquiring rapid remission and reduction of relapse. Treatment compliance should be paid attention to guaranteed, especially during the oral administration courses outside the hospital. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2021
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 18-19
    Abstract: Introduction Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome with a surged cancer incidence, especially in hematologic malignancies, which has been listed in the entity of myeloid neoplasms with germline predisposition in the 2016 revision to the World Health Organization classification of tumors of hematopoietic and lymphoid tissues.Whether FA heterozygotes are predisposed to bone marrow failure and hematologic neoplasm is crucial but unsettled. We therefore retrospectively analyzed rare possibly significant variations (PSVs) in the five most obligated FA genes, BRCA2, FANCA, FANCC, FANCD2, and FANCG, in 788 aplastic anemia (AA) and hematologic malignancies patients to address this issue. Methods Patients diagnosed as AA, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL) from April 2015 to December 2018 in Hebei Yanda Lu Daopei Hospital were enrolled with the ones diagnosed as FA via chromosome breakage test and/or genetic test excluded. Detailed disease histories and workup files were retrieved from the electronic medical record. Amplicon-based high throughput sequencing of aforementioned five genes were performed. The significance of the germline missense variants was assessed by in silico prediction algorithms, including SIFT, Polyphen2, PROVEAN, FATHMM, MutationTaster, and MutationAssessor. Variant predicted as deleterious/possibly deleterious by ≥ 3/6 scoring tools was defined as rare PSV and further included in statistical analysis. For splice site mutations, GeneSplicer, Human Splicing Finder, NetGene2, and FSPLICE were employed and only when ≥2/4 algorithms predict to affect/possibly affect splicing, would the variant be regarded as possibly significant. Same criteria were adopted when stratifying variants recorded in the ExAC. All reported variants in this study were confirmed germline variants by Sanger sequencing with fingernail specimens and/or pedigree analysis. WFisher exact two-tailed test was adopted for variant frequency comparison. Development of disease was analyzed by cumulative incidence method and Kaplan-Meier method. p & lt; 0.05 was considered as statistically significant. Results A total of 788 patients, who were all of the East Asian ancestry, were enrolled, including 341 females and 447 males (Figure 1A). The median age of onset was 10 (1-63), 27 (1-65), 14.5 (1-65), and 6 (1-53) years in AA, MDS, AML, and ALL subgroup, respectively. Sixty-eight variants were identified in 66 patients (8.38%). FANCA is the most frequently mutated gene (n = 29), followed by BRCA2 (n = 20) (Figure 1B). When compared to the ExAC East Asian dataset, there was an overall higher rare PSVs incidence in our cohort (p = 0.016). BRCA2 PSVs showed a higher frequency in ALL (p = 0.038), and FANCA PSVs were significantly enriched in AA and AML subgroups (p = 0.020; p = 0.008). The patients with FANCA heterozygotes also tended to show an increased risk for developing MDS (p = 0.075) (Table 1). No impact of FA-PSV status was found neither on cumulative disease incidence (Figure 1C). FA-PSV + MDS/AML patients have a heavier tumor mutation burden, higher rate of cytogenetic abnormalities, and less epigenetic regulation and spliceosome gene mutations than those of FA-PSV - MDS/AML patients (p = 0.024, p = 0.029, p = 0.024, and p = 0.013) (Figure 1D). Discussion The overall PSVs enrichment in our cohort buttresses that heterozygous mutations of FA genes abate the capacity of DNA homologous recombination repair pathway and contribute to hematopoietic failure. Furthermore, we present the first evidence that BRCA2 heterozygotes have a significantly higher risk of developing into ALL. Instead of all or nothing, the impact of different variant imposed on protein might be seen as a continuous variation. Therefore, contributions of the FA pathway defect could be latent and subtle but be profound as time goes by. We further firstly observed a higher incidence of cytogenetic abnormalities and somatic mutations with statistical significance, and lower frequency of epigenetic regulation and spliceosome gene mutations in FA-PSV + myeloid malignancies. This provides evidence that these FA-PSV carriers are prone to accumulate chromosomal structural abnormalities, and confer the congenital susceptibility of myeloid malignancies. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2020
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: BMC Medical Genetics, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2020-12)
    Abstract: Fanconi anemia (FA) is the most common inherited bone marrow failure (BMF) syndrome with 22 related genes identified. The ALDH2 rs671variant has been proved related to accelerate the progression of BMF in FA patients. The phenotype and genetic basis of Chinese FA patients have not been investigated yet. Methods We analyzed the 22 FA-related genes of 63 BMF patients suspected to be FA. Clinical manifestations, morphological and cytogenetic feathers, ALDH2 genotypes, treatment, and outcomes of the definite cases were retrospectively studied. Results A total of 21 patients were confirmed the diagnosis of FA with the median age of BMF onset was 4-year-old. The number of patients manifested as congenital malformations and growth retardation were 20/21 and 14/21, respectively. BM dysplasia and cytogenetic abnormalities were found in 13/20 and 8/19 patients. All the patients with abnormal karyotypes also manifested as BM dysplasia or had evident blasts. Thirty-five different mutations were identified involving six genes and including twenty novel mutations. FANCA mutations contributed to 66.67% of cases. Eight patients harboring ALDH2 -G/A genotype have a significantly younger age of BMF onset ( p  = 0.025). Within the 19 patients adhering to continuous follow-up, 15 patients underwent hematopoietic stem cell transplantations (HSCTs). During the 29 months of follow-up, 8/19 patients died, seven of which were HSCT-related, and one patient who did not receive HSCT died from severe infection. Conclusions The phenotypic and genetic spectrum of Chinese FA patients is broad. Bone marrow dysplasia and cytogenetic abnormalities are prevalent and highly consistent. The overall outcome of HSCTs is disappointing. Nationwide multicenter studies are needed for the rarity and adverse outcome of this disease.
    Type of Medium: Online Resource
    ISSN: 1471-2350
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 2041359-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: British Journal of Haematology, Wiley, Vol. 191, No. 5 ( 2020-12)
    Type of Medium: Online Resource
    ISSN: 0007-1048 , 1365-2141
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1475751-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 2367-2367
    Abstract: DNTT encodes the most template-independent DNA polymerases TdT. The canonical function of TdT is to boost the diversity of immunoglobulin and T cell receptors by incorporating non-templated nucleotides (NTN) to their variable regions via RAG1/2 mediated DNA breaks and non-homologous end joining (NHEJ) rearrangement process. This study aimed to investigate the relationship between aberrant DNTT expression and illegitimately TdT-aided microhomology-mediated replication-dependent recombination (MMRDR) with the mutagenesis of gene length mutations (LMs) in acute myeloid leukemia (AML), and their prognosis relevance. A cohort of 578 AML cases was enrolled. Fifty healthy donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT), 393 B cell acute lymphoblastic leukemia (B-ALL) cases, 78 T-ALL cases, and 25 mixed-phenotype acute leukemia (MPAL) cases were used as control. Next-generation sequencing was performed for mutation analysis of 86 leukemia driver genes. RNA-seq was used to analyze the expression of DNTT and other non-homologous end joining (NHEJ) associated genes. Prognostic was investigated in a subset of 239 AML cases who underwent anti-thymocyte globulin (ATG) or anti-lymphocyte globulin (ALG) based regimen allo-HSCT. Based on sequence anatomy that considers the MMRDR mechanism and nucleotides characteristics of TdT mediated NTN incorporation, we formulate a classification algorithm for LMs and divide them into four subtypes (type I-IV). Type-I indicates pure duplicated/triplicated germline sequences with identifiable ≥2bp canonical triple microhomology (MH) sequences; type-II indicates pure duplicated/triplicated germline sequences without ≥2bp canonical MH sequences; type-III indicates any LMs with NTN insertions; type-IV indicates any other LMs, mainly deletions. FLT3-LMs has the highest overall incidence and occur across multiple lineage leukemias. We observed a significant FLT3-LMs subtypes distribution bias among acute leukemia subtypes (Figure 1A). Type-I FLT3 LMs are only observed in AML; there are mainly type-III FLT3 LMs in T-ALL and MPAL; type-II, III, IV FLT3 LMs are predominant in B-ALL. The overall DNTT expression was significantly lower in AML than in other leukemia subtypes and control groups (P & lt; 0.001). This supports that FLT3-LMs subtypes distribution bias might be attributed to the difference in the overall DNTT expression among leukemia lineages. A total of 458 LMs events were observed in 295 cases (51.0%) within 25 genes (FLT3, NPM1, CEBPA, RUNX1, KIT, etc.) in our AML cohort. The incidence of type-II and type-III LMs, both of which the mutagenesis relies on TdT-aided MMRDR in theoretically speculate, were 31.2 % and 47.8 %, respectively. Type-I and type-II, which manifested as pure germline sequence duplications, account for 43.6% of the FLT3 LMs; type-III LMs, which with additional inserted NTN sequences, account for as high as 50.4% of the FLT3 LMs. We analyzed the G/C nucleotide contents adjacent to LMs junctions. A significantly high G/C bias was observed at +1 nucleotide position in type-II and type-III subsets (Figure 1B), suggesting that the TdT-aided MMRDR mechanism plays a role in the mutagenesis in these cases. We also observed a strong positive correlation between fragment length and G/C content of the inserted NTN sequences (P & lt; 0.001) within the type-III subset of the 25 LMs genes (Figure 1C), suggesting a higher TdT activity mediates longer inserted sequences. DNTT expressions level of type-III LMs cases were significantly higher than that of type-I, II, IV LMs cases and cases without LMs in the total 25 LMs genes (Figure 1D) and the FLT3 LMs subset. Similar expression signatures of other NHEJ associated genes RAG2, XRCC4, and XRCC6 were also observed. For the survival analysis in the ATG/ALG based regimen allo-HSCT AML subset, we observed a significantly better overall survival (P = 0.024) in cases positive for type-III FLT3-LMs than that of type-I, II (Figure 1E). In this study, we proposed a subclassification algorithm for LMs (type I-IV) in AML. Both DNTT gene expression and sequence character suggesting that TdT-aided MMRDR plays a role in the mutagenesis of type-III and type-II LMs. We also observed AML cases with type-III FLT3 LMs benefit more from ATG/ALG based regimen allo-HSCT than cases with other FLT3 LMs types, which may be attributed to the aberrant lymphoid lineage antigen expression. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2021
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...